Pulmatrix Goodwill and Intangible Assets 2014-2025 | PULM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Pulmatrix goodwill and intangible assets from 2014 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Pulmatrix goodwill and intangible assets from 2014 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$229.3B
Amgen (AMGN)	$159.6B
Gilead Sciences (GILD)	$140.8B
Vertex Pharmaceuticals (VRTX)	$118.7B
Bristol Myers Squibb (BMY)	$90B
CSL (CSLLY)	$82.4B
GSK (GSK)	$76.7B
Regeneron Pharmaceuticals (REGN)	$60.3B
Alnylam Pharmaceuticals (ALNY)	$52.4B
Argenex SE (ARGX)	$41.2B
BioNTech SE (BNTX)	$25.8B
Royalty Pharma (RPRX)	$20.9B
Insmed (INSM)	$20.6B
Biogen (BIIB)	$19.3B
Illumina (ILMN)	$15B
Incyte (INCY)	$14.8B
Genmab (GNMSF)	$14.7B
Genmab (GMAB)	$14B
BioMarin Pharmaceutical (BMRN)	$11.1B
QIAGEN (QGEN)	$11.1B
Moderna (MRNA)	$10.7B
Ascendis Pharma (ASND)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Exelixis (EXEL)	$10B
Exact Sciences (EXAS)	$9B
Verona Pharma American Depositary Share (VRNA)	$9B
Bio-Techne Corp (TECH)	$8.6B
Blueprint Medicines (BPMC)	$8.3B
Roivant Sciences (ROIV)	$7.7B
Halozyme Therapeutics (HALO)	$7.3B